Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

FATAL JAUNDICE AFTER ADMINISTRATION OF BETA-PHENYLISOPROPYLHYDRAZINE

FATAL JAUNDICE AFTER ADMINISTRATION OF BETA-PHENYLISOPROPYLHYDRAZINE The therapeutic usefulness of iproniazid prompted the search for related compounds when hepatotoxicity was reported. One of the newer analogues developed is beta-phenylisopropylhydrazine (Catron), and the following case represents a hepatic reaction with a fatal outcome after its administration. A 65-year-old woman entered the Mount Sinai Hospital with a one-week history of jaundice. The patient, who had severe hypertension, had previously taken many drugs. Six weeks prior to admission she was given 18 mg. a day of beta-phenylisopropylhydrazine for two weeks; then therapy was maintained with 12 mg. a day in addition to chlorothiazide and reserpine. Her blood pressure of 240/120 mm. Hg, which was unresponsive to treatment with chlorothiazide. hydralazine, ganglionic blocking agents, and reserpine, was reduced to 160/90 mm. Hg after two weeks of beta-phenylisopropylhydrazine therapy, and she was symptomatically better. During the week preceding admission, after a total dose of about 600 mg. of beta-phenylisopropylhydrazine, she noted http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

FATAL JAUNDICE AFTER ADMINISTRATION OF BETA-PHENYLISOPROPYLHYDRAZINE

JAMA , Volume 171 (7) – Oct 17, 1959

Loading next page...
 
/lp/american-medical-association/fatal-jaundice-after-administration-of-beta-phenylisopropylhydrazine-8Nfg4iFmHu
Publisher
American Medical Association
Copyright
Copyright © 1959 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1959.73010250003006a
Publisher site
See Article on Publisher Site

Abstract

The therapeutic usefulness of iproniazid prompted the search for related compounds when hepatotoxicity was reported. One of the newer analogues developed is beta-phenylisopropylhydrazine (Catron), and the following case represents a hepatic reaction with a fatal outcome after its administration. A 65-year-old woman entered the Mount Sinai Hospital with a one-week history of jaundice. The patient, who had severe hypertension, had previously taken many drugs. Six weeks prior to admission she was given 18 mg. a day of beta-phenylisopropylhydrazine for two weeks; then therapy was maintained with 12 mg. a day in addition to chlorothiazide and reserpine. Her blood pressure of 240/120 mm. Hg, which was unresponsive to treatment with chlorothiazide. hydralazine, ganglionic blocking agents, and reserpine, was reduced to 160/90 mm. Hg after two weeks of beta-phenylisopropylhydrazine therapy, and she was symptomatically better. During the week preceding admission, after a total dose of about 600 mg. of beta-phenylisopropylhydrazine, she noted

Journal

JAMAAmerican Medical Association

Published: Oct 17, 1959

There are no references for this article.